FDA News: White House Pulls Overton Nomination
The latest fda news is a nomination collapse. The White House said on Tuesday that it had withdrawn the nomination of Dr. Heidi Overton to lead the Food and Drug Administration, pulling the pick on the eve of the Senate vote meant to advance her. The decision, first reported by Axios on Tuesday evening and then confirmed by a White House official, ended a three-month confirmation fight Overton never managed to win, and left the agency without a permanent leader for the seventh month in a row.
Overton, a physician who serves as deputy director of the White House Domestic Policy Council, had been scheduled to face a vote on Wednesday in the Senate Health, Education, Labor and Pensions Committee, the panel known as HELP. By Tuesday, it was clear she did not have the votes. A senior administration official told Axios that Overton lacked the support on Capitol Hill to move forward, and the White House withdrew her name rather than let the committee vote her down. Overton did not respond to requests for comment.
Overton had been nominated in August as a loyalist who could steady an agency that had spent a turbulent year under its first commissioner, Dr. Marty Makary. Instead, she drew opposition from both ends of the Republican coalition: senators who thought she was too close to Trump and Health Secretary Robert F. Kennedy Jr. on vaccines, and figures in Kennedy's own Make America Healthy Again movement who thought she was working against them.
Senate Confirmation Hearings: The Vote That Never Happened
The arithmetic of the HELP Committee is what doomed Overton. The panel has 21 members, 12 Republicans and 11 Democrats, and with Democrats lined up against her, she needed every single Republican to advance. Losing even one would have sunk the nomination, and by Tuesday she appeared to have lost more than one.
The most important vote was the one she could not count on: the committee's chairman, Senator Bill Cassidy of Louisiana, a physician himself. Cassidy had said earlier on Tuesday that he remained undecided about Overton ahead of the Wednesday vote, a remarkable position for a committee chairman the day before the vote. Cassidy had already put his doubts on the record in August, when he described Overton's support for Trump's plan to break up combination vaccines, including the measles, mumps and rubella shot, as almost disqualifying. At her confirmation hearing in September, he pressed her on her scientific independence and on whether she would be willing to push back against Trump and Kennedy, a longtime critic of vaccines.
Two other Republicans were also uncommitted. Senator Susan Collins of Maine told NBC News last week that she was undecided and had not taken a position. Senator Lisa Murkowski of Alaska declined last week to say how she would vote. Both had previously taken issue with the administration's approach to vaccines, and Murkowski had also questioned Overton about abortion-related matters, including the abortion pill mifepristone. With Cassidy, Collins and Murkowski all holding back, the White House could see the count was not there.
The timing mattered for another reason. Republicans have been racing to confirm Trump's remaining nominees before they hand over control of the Senate to Democrats in January, after heavy losses in this month's midterm elections. A failed committee vote would have burned days the White House does not have.
Vaccine News: The Issue That Sank the Nomination
Vaccines defined Overton's nomination from the start, and they ended it. The central problem was the perception, shared by senators in both parties, that she would not break from Trump on his unsupported claims about the dangers of childhood vaccines. She faced bipartisan questions about her willingness to stand apart from the president, and her answers did not settle them.
The flashpoint was the administration's plan to break up combination vaccines, the shots that protect children against several diseases at once. The best-known is the measles, mumps and rubella vaccine, a single shot that has been a cornerstone of childhood immunisation for decades. Trump has pushed to split such combinations into separate shots, and Overton backed the idea. Cassidy, who worked as a doctor before entering politics, called that position almost disqualifying when Overton was first nominated, and he returned to the subject at her September hearing.
Cassidy's leverage over health nominees has been a recurring feature of this administration. He has repeatedly tried to win commitments to uphold vaccine standards from the president's health picks, including from Kennedy himself, by threatening to withhold his vote, and in the end he voted in favour of each nominee that came before his committee. Overton may have been the exception, and the politics of his own position help explain why. Cassidy lost a primary race in June in his bid for a third term, and with only weeks left in his Senate career, he faced little downside in opposing the latest FDA nominee.
The vaccine fight also exposed the gap between Overton and the public health establishment. The FDA decides which vaccines reach the American public, and its commissioner sets the tone for how the government talks about them. Senators wanted to know whether Overton would defend the agency's scientific judgments when they conflicted with the White House, and her record as a domestic policy adviser, spent working directly for Trump or for conservative groups aligned with his agenda, gave them reason to doubt that she would.
Vapes and the MAHA Split
Vaccines were not the only problem. Overton also drew fire for her role in loosening restrictions on vaping products, a record that put her at odds with senators who worry about nicotine addiction among young people. The vaping issue carried an extra sting because it was tangled up in the departure of her predecessor. Makary resigned in May, in part because of the administration's decision to authorise several fruit-flavoured vaping products, and Overton had been involved in the same policy area. Critics described her as having ties to big tobacco interests.
Perhaps the most surprising opposition came from inside the administration's own health movement. Several influential figures in the Make America Healthy Again movement blamed Overton and other White House officials for sidelining some of Kennedy's top health goals. Earlier this month, Calley Means told the podcaster Joe Rogan that White House aides, including Overton, had worked to advance a Supreme Court decision blocking thousands of lawsuits over the weedkiller glyphosate, and he said the policy was carried out at the behest of industry lobbyists. There is a very concentrated group in the Trump administration that are antagonistic to what people voted for, Means said.
RFK Jr News: The Search for a Replacement Begins
With Overton gone, the search for a new FDA commissioner has already begun, and the first name to surface is a familiar one. Kennedy recently reached out to Senator Roger Marshall of Kansas about taking Overton's place, according to a person familiar with the matter. Marshall, an obstetrician, is the chair of the Senate's Make America Healthy Again caucus, which would make him a natural fit for the administration's health agenda, but he is a complicated choice.
Marshall recently lost what had historically been a safe Senate seat for Republicans to Democrat Adam Hamilton, a pastor, and he has not won broad support from the MAHA movement despite chairing its Senate caucus, in part because of his support for the pesticide glyphosate. The same glyphosate fight that helped sink Overton would follow Marshall into any confirmation process. The White House has not said whether Marshall is a serious candidate or simply one of several names under consideration, and no announcement is expected while the president is abroad.
The FDA is meanwhile being led on an acting basis by Kyle Diamantas, an attorney and a friend of Donald Trump Jr., elevated by the president after serving as the agency's top food official. Diamantas has been running the agency since Makary stepped down in May, and he will continue to do so while the White House looks for a permanent commissioner.
Health News: A Pattern of Pulled Nominations
Overton's withdrawal fits a pattern that has dogged Trump's health picks from the start of his second term. The White House has previously pulled several other health nominations when it became clear the Senate would not confirm them. Trump's first nominee for the Centers for Disease Control and Prevention, Dr. David Weldon, was replaced because it was unclear he had enough Republican support. Two of Trump's surgeon general nominees were also pulled after facing pushback from Senate Republicans, including Dr. Casey Means, the sister of Calley Means, whose criticism of Overton helped sink her nomination.
The agency she would have led is in a fragile state. Under Makary, the FDA was marked by a string of scientific disputes, leadership changes and reports of low morale among staff. The agency has lost about 20 percent of its employees to layoffs, buyouts, retirements or resignations since Trump took office, a hollowing-out that has left it thinner at precisely the moment it faces decisions on vaccines, vaping, abortion medication and a wave of new drugs. Whoever takes the job next will inherit an agency that needs rebuilding as much as it needs leadership.
What Happens Next
The immediate consequence is simple: the Wednesday vote in the HELP Committee will not happen, and the FDA will remain without a permanent commissioner. The White House must now find a candidate who can win all 12 Republicans on the committee or attract at least one Democrat, with the clock running down toward the January handover. The next nominee will face the same questions Overton faced, about vaccines, about independence from the White House, and about the MAHA agenda.
The mifepristone review is the most pressing item on the agency's calendar. The safety review is due to finish in March, and the decision will shape access to medication abortion across the country. An acting commissioner can oversee the review, but a decision of that magnitude would carry more weight from a Senate-confirmed leader. The same is true of the vaccine schedule, where the administration's plans to rework combination vaccines remain on the table, and of the vaping rules that helped end Makary's tenure.
For Cassidy, the episode is a final assertion of authority in the closing weeks of his Senate career. For Kennedy, it is a reminder that the MAHA movement's influence has limits, and that the White House's own aides can become its targets. The agency that approves the medicines, vaccines and food safety rules for the entire country is being run by an acting commissioner, its workforce is a fifth smaller than it was a year ago, and the search for its next leader is starting over.
Source: Associated Press